Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134145 | 0.78 | HSD11B1 (0.67) | HSD11B1NR3C2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL3676532 | 0.77 | HSD11B1 (0.47) | HSD11B1NR3C2ALDH1A1HPGDMLYCD | |
| SCHEMBL16618343 | 0.77 | CES2 (0.56) | HSD11B1ALDH1A1L3MBTL1POLBCES2 | |
| SCHEMBL23699763 | 0.76 | HSD11B1 (0.50) | HSD11B1NR3C2ALDH1A1HPGDMLYCD | |
| SCHEMBL25984798 | 0.76 | NR3C2 (0.53) | HSD11B1NR3C2ALDH1A1HPGDMLYCD | |
| SCHEMBL28730355 | 0.76 | HSD11B1 (0.50) | HSD11B1NR3C2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL2351713 | 0.74 | HSD11B1 (0.52) | HSD11B1ALDH1A1HPGDPOLBCES2 | |
| SCHEMBL3377195 | 0.73 | MLYCD (0.50) | HSD11B1ALDH1A1HPGDMLYCDPOLB | |
| SCHEMBL956511 | 0.73 | CES1 (0.50) | HSD11B1ALDH1A1HPGDL3MBTL1POLB | |
| SCHEMBL9000097 | 0.73 | HSD11B1 (0.51) | HSD11B1NR3C2ALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256449-A2 | SODIUM CHANNEL BLOCKERS | Daewoong Pharmaceutical Co., Ltd. (KR) | 2017-12-20 | — | — | EP | claimed |
| WO-2016129933-A2 | SODIUM CHANNEL BLOCKERS | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-18 | — | — | WO | claimed |
| EP-3256449-A2 | SODIUM CHANNEL BLOCKERS | Daewoong Pharmaceutical Co., Ltd. (KR) | 2017-12-20 | — | — | EP | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2016129933-A2 | SODIUM CHANNEL BLOCKERS | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-18 | — | — | WO | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015051043-A1 | BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| CN-1066843-A | Weedicide | RHONE POULENC AGRICULTURE (GB) | 1992-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | HSD11B1 1570/4885NR3C2 484/4885ALDH1A1 643/4885 |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | HSD11B1 1709/4885NR3C2 2015/4885ALDH1A1 638/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | HSD11B1 568/4885NR3C2 944/4885ALDH1A1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.